GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Steminent Biotherapeutics Inc (ROCO:7729) » Definitions » Retained Earnings

Steminent Biotherapeutics (ROCO:7729) Retained Earnings : NT$-814.27 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Steminent Biotherapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Steminent Biotherapeutics's retained earnings for the quarter that ended in Dec. 2024 was NT$-814.27 Mil.

Steminent Biotherapeutics's quarterly retained earnings declined from Dec. 2023 (NT$-655.53 Mil) to Jun. 2024 (NT$-739.13 Mil) and declined from Jun. 2024 (NT$-739.13 Mil) to Dec. 2024 (NT$-814.27 Mil).

Steminent Biotherapeutics's annual retained earnings declined from Dec. 2022 (NT$-526.30 Mil) to Dec. 2023 (NT$-655.53 Mil) and declined from Dec. 2023 (NT$-655.53 Mil) to Dec. 2024 (NT$-814.27 Mil).


Steminent Biotherapeutics Retained Earnings Historical Data

The historical data trend for Steminent Biotherapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steminent Biotherapeutics Retained Earnings Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
-316.62 -440.82 -526.30 -655.53 -814.27

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial -526.30 -568.45 -655.53 -739.13 -814.27

Steminent Biotherapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Steminent Biotherapeutics  (ROCO:7729) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Steminent Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.

Steminent Biotherapeutics Headlines

No Headlines